AgomAb Therapeutics NV (AGMB) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on AgomAb Therapeutics NV (AGMB) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.73 of bullish evidence against -0.42 bearish.

AgomAb Therapeutics NV last closed at $8.69, +1.52% on the session.

Against the IVW growth benchmark the position is +0.60% over the forecast window.

The read is built from 13 underlying insights — 2 bullish and 11 bearish.

Agreement across those insights is 85%.

16 graded predictions for AGMB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

AgomAb Therapeutics NV is classified under Health Care / Pharmaceuticals, with a market capitalisation of $421.56M.

StockMap tracks AgomAb Therapeutics NV as the 70th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite AgomAb Therapeutics NV ranks 68th of 128 in the group, against a group median of -0.24.